Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine

Influenza B Virus With Modified Hemagglutinin Cleavage Site as a Novel Attenuated Live Vaccine

(2011) Jürgen Stech et al.   JOURNAL OF INFECTIOUS DISEASES

Cell-culture-derived influenza vaccine production

(2011) W Paul Glezen   LANCET

Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial

(2011) P Noel Barrett et al.   LANCET

Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: Immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination

(2011) Heimo Lagler et al.   VACCINE

Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children

(2010) Yuji Yasuda et al.   ADVANCES IN THERAPY

Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process

(2010) Meena George et al.   BIOTECHNOLOGY AND BIOENGINEERING

Clinical Efficacy of Cell Culture–Derived and Egg‐Derived Inactivated Subunit Influenza Vaccines in Healthy Adults

(2010) Sharon Frey et al.   CLINICAL INFECTIOUS DISEASES

Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses

(2010) Aseem Pandey et al.   Human vaccines & immunotherapeutics

Influenza Virus–Cytokine‐Protease Cycle in the Pathogenesis of Vascular Hyperpermeability in Severe Influenza

(2010) Siye Wang et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial

(2010) Karl G Nicholson et al.   LANCET INFECTIOUS DISEASES

Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example

(2009) Jiří Beran et al.   BMC INFECTIOUS DISEASES

Reverse genetics-generated elastase-dependent swine influenza viruses are attenuated in pigs

(2009) A. Masic et al.   JOURNAL OF GENERAL VIROLOGY

Safety and Immunogenicity of a Novel Influenza Subunit Vaccine Produced in Mammalian Cell Culture

(2009) Agnieszka Szymczakiewicz‐Multanowska et al.   JOURNAL OF INFECTIOUS DISEASES

Subunit Influenza Vaccines Produced from Cell Culture or in Embryonated Chicken Eggs: Comparison of Safety, Reactogenicity, and Immunogenicity

(2009) Keith S. Reisinger et al.   JOURNAL OF INFECTIOUS DISEASES

A Cell Culture (Vero)–Derived H5N1 Whole‐Virus Vaccine Induces Cross‐Reactive Memory Responses

(2009) Hartmut J. Ehrlich et al.   JOURNAL OF INFECTIOUS DISEASES

Historical Perspective — Emergence of Influenza A (H1N1) Viruses

(2009) Shanta M. Zimmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine

(2009) Arvydas Ambrozaitis et al.   VACCINE

Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults

(2009) Wendy A. Keitel et al.   VACCINE

Development of a live-attenuated influenza B ΔNS1 intranasal vaccine candidate

(2009) Nina Wressnigg et al.   VACCINE

Current challenges in implementing cell-derived influenza vaccines: Implications for production and regulation, July 2007, NIBSC, Potters Bar, UK

(2009) Philip D. Minor et al.   VACCINE

A phase I clinical trial of a PER.C6® cell grown influenza H7 virus vaccine

(2009) Rebecca J. Cox et al.   VACCINE

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial

(2009) Wendy Keitel et al.   VACCINE

Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines

(2008) M. Keith Howard et al.   BIOLOGICAL CHEMISTRY

Cell-Based Influenza Vaccines

(2008) Jennifer M Audsley et al.   DRUGS

Effectiveness of Inactivated Influenza Vaccines Varied Substantially with Antigenic Match from the 2004–2005 Season to the 2006–2007 Season

(2008) Edward A. Belongia et al.   JOURNAL OF INFECTIOUS DISEASES

A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture

(2008) Hartmut J. Ehrlich et al.   NEW ENGLAND JOURNAL OF MEDICINE

A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines

(2008) Jens-Peter Gregersen   VACCINE

Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: A sequential Phase I and Phase II clinical trial

(2008) N. Groth et al.   VACCINE

The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine

(2007) G. Gabriel et al.   VACCINE